Back to News
Market Impact: 0.35
FDA Accepts UniQure's BLA For Huntington's Gene Therapy; PDUFA Date In May '27
Source: Nasdaq
Healthcare & BiotechRegulation & Legislation
The FDA accepted uniQure’s biologics license application for ifezuntirgene inilparvovec, a gene therapy being developed to treat Huntington’s disease. Acceptance is a regulatory milestone, not an approval; the article provides no review timeline or market reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
QURE0.65
More News
- 5 things to watch on Election Day as Democrats push for control of Congress
- Investors poised for possible Democratic gains in Congress as US awaits election results
- Texas race results could kick AI trade while it's already down
- Analysts react to US midterm election results
- Fannie Mae, Freddie Mac rally as Ackman presses for conservatorship exit
- Meta says automation wrongly took down No Kings and a Senate candidate’s page. It’s automating more anyway